Blocks voltage-gated potassium channels Kv7.4/KCNQ4 (IC(50)=2.5 uM), Kv7.1/KCNQ1 (IC(50)=2.8 uM), Kv7.2/KCNQ2 (IC(50)=2.7 uM) and Kv7.5/KCNQ5 (IC(50)=2.7 uM). Targets the pore domain, in particular negatively charged residues 'Asp-266' and 'Asp-288', of KCNQ4 and probably other KCNQ channel family members where these residues are conserved. In vivo, shows vasoconstrictive activity resulting in acute hypertension when injected intravenously in mice. Also induces coronary vasospasms ultimately leading to heart failure. Induces seizures when injected into the hippocampus of mice. Decreases respiratory rate while increasing respiratory amplitude, probably by triggering a contraction of the bronchial ring. Expressed by the venom gland. Has the structural arrangement of an alpha-helix connected to a beta-sheet by disulfide bonds (CSalpha/beta). Since the toxin contains only 2 disulfide bonds, it is called 2ds-CSalpha/beta. LD(50) is 0.85 mg/kg when injected intravenously in mice. Does not inhibit channels TRPV1 and TRPV2, voltage-gated potassium channels Kv2.1/KCNB1 and Kv4.1/KCND1, hERG, tetrodotoxin (TTX)-sensitive and TTX-insensitive sodium channels in DRG neurons or voltage-gated calcium channels in DRG neurons. Belongs to the scoloptoxin-15 family.